MediWound Story

<div class='circular--portrait' style='background:#B0CBFE;color: #ffffff;font-size:4em;'>ME</div>
MDWD -- USA Stock  

USD 3.80  0.08  2.09%

With so much uncertainty about the healthcare space, it is fair to digest MediWound against current market trends. As expected, MediWound is starting to reaffirm its true potential as shareholders are becoming more and more confident in the future outlook. The returns on investing in MediWound and the market returns of the last few months appear uncorrelated. Unsteady basic indicators of the firm may also indicate signs of longer-term losses for MediWound shareholders. MediWound is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 12th of November 2020.
Published over a week ago
View all stories for MediWound | View All Stories
Should you buy MediWound (NASDAQ:MDWD) based on latest technical indicators?
This firm's average rating is Strong Buy from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on MediWound market sentiment investors' perception of the future value of MediWound. Let us look at a few aspects of MediWound technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of MediWound. In general, we focus on analyzing MediWound stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MediWound's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of MediWound's intrinsic value. In addition to deriving basic predictive indicators for MediWound, we also check how macroeconomic factors affect MediWound price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does MediWound Stands against Peers?

Analyzing MediWound competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to MediWound across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out MediWound Competition Details

How MediWound utilizes its cash?

To perform a cash flow analysis of MediWound, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash MediWound is receiving and how much cash it distributes out in a given period. The MediWound cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. MediWound Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 8.29 Million

Closer look at MediWound Downside Variance

MediWound has current Downside Variance of 12.83. Downside Variance (or DV) is measured by target semi-variance and is termed downside volatility. It is expressed in percentages and therefore allows for rankings in the same way as variance. One way to view downside volatility is the annualized variance of returns below the target.

Downside Variance is the probability-weighted squared below-target returns. The squaring of the below-target returns has the effect of penalizing failures at an exponential rate. This is consistent with observations made on the behavior of individual decision-making under.

Downside Variance 
 = 
SUM(RET DEV)2 
N(ER) 
 = 
12.83
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N(ER) = Number of points with returns less than expected return for the period
Let's now compare MediWound Downside Variance to its closest peers:
MDWD
DRNA
DNLI
DTIL
MDWD12.828003254482455
DRNA8.7
DNLI9.37
DTIL15.41

Can MediWound build up on the latest surge?

Mean deviation is down to 3.29. It may indicate a possible volatility dip. MediWound shows above-average downside volatility for the selected time horizon. We advise investors to inspect MediWound further and ensure that all market timing and asset allocation strategies are consistent with the estimation of MediWound future alpha.

Our Final Take On MediWound

Although few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, MediWound may offer a potential longer-term growth to shareholders. The inconsistency in the assessment between current MediWound valuation and our trade advice on MediWound is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to MediWound.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of MediWound. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com